Document is current
Any future updates will be listed below
-
Authors
Moosavi, Shahrzad
Borema, Troy
Ewesuedo, Reginald
Harris, Stuart
Levy, Jeffrey
May, Thomas B.
Summers, Martin
Thomas, Jeffrey S.
Zhang, Jeffrey
Yao, Hsuan-Ming https://orcid.org/0000-0002-1652-2749
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02629289 at ClinicalTrials.govnct03273842 at ClinicalTrials.govDocuments that mention this clinical trial
PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta®): Pharmacodynamics, Pharmacokinetics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers
https://doi.org/10.1007/s12325-020-01387-x
Documents that mention this clinical trial
PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta®): Pharmacodynamics, Pharmacokinetics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers
https://doi.org/10.1007/s12325-020-01387-x
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 8 April 2020
First Online: 10 June 2020
